Revelation Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Kyiv entering 'survival' mode amid Russian strikes surge: mayor tells AFP
-
Argentina friendlies no fairy tale for African footballers
-
Verdict due in Mexico trial over murders of Australia, US surfers
-
US suspending Microsoft from visa program: Vance
-
B2PRIME Welcomes Christina Barbash as Commercial Manager
-
Man City must 'stick together' during crisis, says Haaland
-
Russia forcing Kyiv into 'survival' mode before winter, mayor tells AFP
-
CAS opens hearing into Senegal AFCON title appeal
-
Closing arguments begin in Maradona death trial
-
UK police agree searches for ex-prince Andrew's homes 'unlawful': judge
-
UEFA president Ceferin to stand for re-election in 2027
-
After botched US execution, Christa Pike walking, mentally 'foggy': lawyer
-
Nearly 300,000 Nepalis at flood risk: study
-
'Stunned' Madrid mourns pensioner who sparked housing protests
-
Riyadh kindergarten hit by interception debris as Houthis say targeted airport
-
High school students turn out for new protests across France
-
Alex Bodi mizează, alături de CRIF, pe investiții transparente și pe prevenirea riguroasă a spălării banilor
-
Bid by Italy's Intesa bank to take over MPS gets boost
-
Gulf Labs, Part of Thailand’s $27 Billion GULF Group, Goes Live as an Injective Validator
-
Stablecoins Are Quietly Becoming Business Infrastructure, NOWPayments Data Shows
-
EU okay for winter despite 'historically low' gas stocks: operators
-
Oil surges, stocks sink as US reportedly eyes new Iran strikes
-
Rwanda to host F1 Grand Prix: sources close to both sides
-
Woman in botched US execution walking, mentally 'foggy': lawyer
-
EU top diplomat says bloc in favour of UN Lebanon peacekeepers' extension
-
Farhan hopes Pakistan's new combination takes off in Sri Lanka T20Is
-
Antonelli and Russell to run different Mercedes aero packages in Singapore
-
Teenager Andreeva seals China Open semi-final with Bartunkova
-
WTO hikes 2026 trade growth forecast on AI boom
-
Britain's Burnham says open to Germany joining warplane project
-
'I love that challenge': Hamilton prays for rain in Singapore
-
Kovac's tough love has Dortmund dreaming of title charge
-
G.Bissau moves towards postponement of December general election
-
China announces candidate for WHO chief
-
Verstappen out to settle 'unfinished business' at Singapore Grand Prix
-
South Korea test-fires its first homegrown hypersonic weapon: presidency
-
WhiteBIT Launches Bitcoin Lightning Network Support, Powered by Voltage
-
ONAR Advances Nasdaq Listing Preparation Following Advertise Purple Acquisition and Financing
-
Oil surges, stocks sink as US reportedly eyes fresh Iran strikes
-
Thailand opens extradition process for reporter sought by China
-
Anne Carson: modern takes on Greek classics
-
France struggles to wean social housing off gas
-
Canada's Anne Carson wins Nobel literature prize
-
Germany lifts GDP forecast as economy withstands Iran war
-
Ethiopia drones hit Eritrean troops in Tigray
-
Sri Lanka appoints Kusal Mendis as Test captain
-
Russian strike on buses kills 30 in frontline Ukrainian city
-
Norris confident McLaren can shine in Singapore
-
Thailand begins extradition process against Chinese journalist
-
Alex Bodi pushes ahead with expansion: ALIX LASERS showroom planned for Bucharest
Revelation Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, CA / ACCESS Newswire / July 21, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company developing innovative solutions to treat acute and chronic disease, today announced that on July 15, 2026, the Compensation Committee of Revelation's Board of Directors approved three inducement grants totaling 108,000 restricted stock units ("RSUs") covering 108,000 shares of the Company's common stock to three newly hired non-executive employees. The inducement grants were granted pursuant to the Revelation Biosciences, Inc. 2026 Equity Inducement Plan ("2026 Inducement Plan"). The awards were granted as a material inducement to the employees' acceptance of employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
The RSUs will vest over two years in equal quarterly installments, with the first installment vesting on October 15, 2026, and the final installment vesting on July 15, 2028, subject to the employee's continued employment or service with the Company through the vesting dates. The RSUs are subject to the terms and conditions of the 2026 Inducement Plan and the terms and conditions of the restricted stock unit agreement covering the grants.
About Revelation Biosciences, Inc.
Revelation Biosciences, Inc. is a clinical-stage life sciences company focused on rebalancing inflammation using its proprietary formulation, Gemini. Revelation has multiple ongoing programs to evaluate Gemini as a treatment for acute kidney injury, a treatment of chronic kidney disease, prevention of post-surgical infection, and a treatment to reduce hyperinflammation and infection associated with severe burn.
For more information, please visit www.RevBiosciences.com.
Company Contacts:
Mike Porter
Investor Relations
Porter LeVay & Rose Inc.
Email: [email protected]
Chester Zygmont, III
Chief Financial Officer
Revelation Biosciences Inc.
Email: [email protected]
SOURCE: Revelation Biosciences Inc.
View the original press release on ACCESS Newswire
S.Gregor--AMWN
